{"id":"W4310554573","doi":"10.1016/s1470-2045(22)00687-8","title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Vemurafenib; Atezolizumab; Interim analysis; Placebo; Internal medicine; Tolerability; Oncology; Adverse effect; Surgery; Randomized controlled trial; Metastatic melanoma; Pembrolizumab; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005745491,0.0001537986,0.0005968349,0.0001599201,0.00007426586,0.000007849265,0.0001716562,0.00004918581,0.00006197421],"category_scores_gemma":[0.0000493604,0.000111881,0.00004041628,0.0003523509,0.00009217251,0.000007863659,0.0001186054,0.0001606448,2.92465e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006679714,"about_ca_system_score_gemma":0.00009681909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002006753,"about_ca_topic_score_gemma":0.0170622,"domain_scores_codex":[0.9983956,0.0006155449,0.000319395,0.0003249646,0.0001303635,0.0002140808],"domain_scores_gemma":[0.9991865,0.0002267915,0.0002464225,0.0002441502,0.00006213279,0.00003406683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4932207,0.01672578,0.2798772,0.0002258166,0.005853089,0.001169876,0.02841814,0.03535993,0.1186424,0.0007811613,0.0001512664,0.01957463],"study_design_scores_gemma":[0.5358183,0.05845401,0.3573609,0.00005633083,0.001318731,0.0001404747,0.01031911,0.009718267,0.02196665,0.0001142191,0.003878337,0.0008546236],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997758,0.0001673706,0.0001900436,0.0001975268,0.00005074315,0.00102912,0.0001034558,0.000005734182,0.0004980235],"genre_scores_gemma":[0.9990169,0.00003933955,0.0001514279,0.0001253802,0.00002410997,0.0002532569,0.0003154347,0.00001333473,0.00006083133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09667577,"threshold_uncertainty_score":0.9521108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01725053882236342,"score_gpt":0.2996574736859282,"score_spread":0.2824069348635648,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}